Empiric Carbapenems for Nosocomial Pneumonia: Is Hindsight Clearer in 2020?

Chest. 2021 Mar;159(3):897-899. doi: 10.1016/j.chest.2020.11.003.

Authors

Nathaniel J Rhodes¹, Richard G Wunderink²

Affiliations

¹ Department of Pharmacy Practice, Chicago College of Pharmacy, and Pharmacometrics Center of Excellence, Midwestern University, Downers Grove, IL; Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL. Electronic address: nrhode@midwestern.edu.
² Department of Medicine, Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.

PMID: 33678269
DOI: 10.1016/j.chest.2020.11.003

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anti-Bacterial Agents / therapeutic use
Carbapenems / therapeutic use
Cross Infection* / drug therapy
Cross Infection* / epidemiology
Healthcare-Associated Pneumonia* / drug therapy
Healthcare-Associated Pneumonia* / epidemiology
Humans

Substances

Anti-Bacterial Agents
Carbapenems